Abstract
Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Current Alzheimer Research
Title:Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice
Volume: 11 Issue: 10
Author(s): Elise Levigoureux, Sophie Lancelot, Caroline Bouillot, Fabien Chauveau, Mathieu Verdurand, Jeremy Verchere, Thierry Billard, Thierry Baron and Luc Zimmer
Affiliation:
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Abstract: Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Export Options
About this article
Cite this article as:
Levigoureux Elise, Lancelot Sophie, Bouillot Caroline, Chauveau Fabien, Verdurand Mathieu, Verchere Jeremy, Billard Thierry, Baron Thierry and Zimmer Luc, Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107154201
DOI https://dx.doi.org/10.2174/1567205011666141107154201 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Chemical Shift Imaging for AD
Current Medical Imaging Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Pharmacological Effects of Biotin in Animals
Mini-Reviews in Medicinal Chemistry Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Treatment of Allergic Rhinitis in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Untangling Alzheimer’s Disease Clinicoanatomical Heterogeneity Through Selective Network Vulnerability – An Effort to Understand a Complex Disease
Current Alzheimer Research Unveiling Cancer in IBD: Screening Colonoscopy or Chromoendoscopy
Current Drug Targets Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets